

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Thibaut VERJAT

Application No.: 10/579,986

Filed: May 19, 2006

Docket No.: 127999

For: METHOD FOR DIAGNOSIS/PROGNOSIS OF BREAST CANCER

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.

Respectfully submitted,

  
William P. Berridge  
Registration No. 30,024

Scott M. Schulte  
Registration No. 44,325

WPB:SMS/kam

Date: June 30, 2006

**OLIFF & BERRIDGE, PLC**  
**P.O. Box 19928**  
**Alexandria, Virginia 22320**  
**Telephone: (703) 836-6400**

<p><b>DEPOSIT ACCOUNT USE AUTHORIZATION</b> Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461</p>
---

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 127999		APPLICATION NO. 10/579,986	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)				APPLICANT(S) Thibaut VERJAT			
				FILING DATE May 19, 2006			
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Name			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation	
OTHER DOCUMENTS							
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)					
	1	Price, Royden E., et al. (March, 1991). <i>Human cyclophilin B: A second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence.</i> Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 1903 - 1907.					
	2	Mishra, Sandip K., et al. (October, 2001). <i>Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells.</i> FEBS Letters, 507, pp. 88 - 94.					
	3	Suo, Zhehe, et al. (February, 2001). <i>Estrogen receptor-<math>\alpha</math> and C-ERBB-4 expression in breast carcinomas.</i> Vindows Arch, 439; 62 - 69.					
	4	Swan, David C., et al. (Apri, 1997). <i>A Sensitive, Type-Specific, Fluorogenic Probe Assay for Detection of Human Papillomavirus DNA.</i> Journal of Clinical Microbiology, Vol. 35, pp.886 - 891.					
	5	Iwao, Kyoko, et al. (October 15, 2000). <i>Quantitative Analysis of Estrogen Receptor-<math>\alpha</math> and -<math>\beta</math> Messenger RNA Expression in Breast Carcinoma by Real-Time Polymerase Chain Reaction.</i> Cancer, Vol. 89, Number 8, pp. 1732 - 1738.					
	6	Kurebayashi, Junichi, et al. (February, 2000) <i>Expression Levels of Estrogen Receptor-<math>\alpha</math>, Estrogen Receptor-<math>\beta</math>, Coactivators, and Corepressors in Breast Cancer.</i> Clinical Cancer Research, Vol. 6, pp. 512 - 518.					
	7	Compton, J. (March 7, 1991). <i>Nucleic acid sequence-based amplification.</i> Nature, Vol. 350, 91 & 92.					
	8	Tyagi, Sanjay, and Kramer, Fred R. (March, 1996). <i>Molecular Beacons: Probes that Fluoresce upon Hybridization.</i> Nature Biotechnology, Vol. 14, 303 - 308.					
	9	Kricka, Larry J. (1999). <i>Nucleic Acid Detection Technologies-- Labels, Strategies, and Formats.</i> Clinical Chemistry, Vol. 45, No. 4, pp. 453 - 458.					
	10	Giulietti, Annapaula, et al. (2001). <i>An Overview of Real-Time Quantitative PCR: Applications to Quantify Cytokine Gene Expression.</i> Methods, 25, pp. 386 - 401.					
	11	Bustin, S.A. (2002). <i>Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems.</i> Journal of Molecular Endocrinology, 29, pp. 23 - 39.					
	12	Levison, Peter R. (1998). <i>New approaches to the isolation of DNA by ion-exchange chromatography.</i> Journal of Chromatography A, 827, pp. 327 - 344.					
	13	Boom, R. (March, 1990). <i>Rapid and Simple Method for Purification of Nucleic Acids.</i> Journal of Clinical Microbiology, pp. 495 - 503.					

14	Nielsen, Peter E. (December 6, 1991). <i>Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide</i> . Science, Vol. 254, pp. 1497 -1500.
15	Poola, Indra, et al. (1997). <i>Quantitation of Estrogen Receptor mRNA Copy Numbers in Breast Cancer Cell Lines and Tumors</i> . Analytical Biochemistry, Vol. 258, pp. 209 - 215.
16	Fasco, Michael J. (1997). <i>Quantitation of Estrogen Receptor mRNA and Its Alternatively Spliced mRNAs in Breast Tumor Cells and Tissues</i> . Analytical Biochemistry, Vol. 245, pp. 167 - 178.
17	Fuqua, S.A.W., et al. (May 16, 1990). <i>Sensitive Detection of Estrogen Receptor RNA by Polymerase Chain Reaction Assay</i> . Journal of the National Cancer Institute, Vol. 82, No. 10, pp. 858 - 861.
18	Slamon, Dennis J. , et al. (January 9, 1987). <i>Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the Her-2/neu Oncogen</i> . Science, Vol. 235, pp. 177 - 182.
19	Horwitz, Kathryn B., et al. (N.D.). <i>Progestin Action and Progesterone Receptor Structure in Human Breast Cancer: A Review</i> . Recent Progress in Hormone Research, Vol. 41, pp. 249 - 317.
20	Goldhirsch, John H. , et al. (September 15, 2001). <i>Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer</i> . Journal of Clinical Oncology, Vol. 19, No. 18, pp. 3817 - 3827.
21	Osborne, C. Kent, M.D. (1998). <i>Steroid hormone receptors in breast cancer management</i> . Breast Cancer Research and Treatment, 51, pp. 227 - 238.
22	Keller, George H. , & Manak, Mark M. (N.D.). <i>DNA Probes</i> . pp. 173 - 253.
EXAMINER	
DATE CONSIDERED	
Examiner:	Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.